Nutriband Inc. Warrant - NTRBW STOCK NEWS

Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for its AVERSA™ trademark, a key component of its abuse-deterrent transdermal patch technology. The company's lead product, AVERSA™ Fentanyl, is progressing towards commercial manufacturing scale-up in partnership with Kindeva Drug Delivery. Nutriband plans to file an IND application with the FDA, preceding pivotal studies to demonstrate the abuse-deterrent properties of AVERSA™ Fentanyl.

The upcoming human abuse potential study will compare AVERSA™ Fentanyl to a current fentanyl patch without abuse-deterrent features. Preliminary studies indicate AVERSA™ technology's high resistance to manipulation. A market analysis projects potential peak annual U.S. sales of $80 million to $200 million for AVERSA™ Fentanyl, highlighting its significant market potential in abuse-deterrent pharmaceuticals.

Nutriband has provided an update on its Aversa Fentanyl product development program. The company, in collaboration with Kindeva Drug Delivery, has progressed in developing the commercial manufacturing process for a transdermal fentanyl patch incorporating Nutriband's AVERSA™ abuse-deterrent technology. This follows a feasibility agreement and a commercial development and clinical supply agreement between the two companies.

Kindeva has validated analytical methods for handling aversive agents required for the product. Nutriband plans to file an Investigational New Drug (IND) application with the FDA, including chemistry, manufacturing, and clinical study protocols for a Phase 1 human abuse potential study, which is pivotal for the New Drug Application (NDA) process. No Phase 2 or Phase 3 trials are needed.

The AVERSA Fentanyl patch aims to prevent drug misuse while ensuring accessibility for patients in need, with potential peak annual US sales estimated between $80 million to $200 million.

Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.

In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.

The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.

Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.

Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.

Investors can register for the free webinar and submit questions beforehand or during the live session.

Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.

Nutriband Inc. announced the closing of an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, an abuse-deterrent opioid patch. The company aims to reach peak annual US sales of $80 million to $200 million. Nutriband is working with Kindeva Drug Delivery to develop the commercial manufacturing process for the product. The development milestones include FDA IND filing, pivotal human abuse potential clinical study, and NDA filing. The company targets Q1 of 2025 for NDA submission. Nutriband's AVERSA technology shows promising abuse-deterrent properties in preliminary studies. The company plans to file a 505(b)(2) NDA based on a single Phase 1 human abuse potential clinical study, potentially receiving expedited FDA review. Nutriband's pipeline includes abuse deterrent versions of fentanyl, buprenorphine, and methylphenidate transdermal patches.

Nutriband Inc. has signed an exclusive supplier agreement with Fit For Life Group, a major brand license holder, for the launch of a new product under one of their top brands. The agreement was fully executed on April 19, 2024. Nutriband's subsidiary, Active Intelligence, will serve as the manufacturer. Fit For Life Group, founded in 2016, is a prominent player in the fitness equipment and yoga accessories market, with a strong brand portfolio including Gaiam, Reebok, Adidas, New Balance, SPRI, and FILA. They target a wide range of consumers from beginners to professionals, with distribution through major retailers like Target, Walmart, Dick's Sporting Goods, and Amazon.

Nutriband Inc. has announced an $8.4M private placement to fund the development of AVERSA™ Fentanyl and target FDA approval in Q1 2025. The company has entered into securities purchase agreements for the sale of 2,100,000 shares of common stock at $4 per share, with investors receiving warrants to purchase additional shares at $6.43 per share.

Nutriband Inc. announces engagement with Fit For Life Group, a major brand license holder, for manufacturing innovative products. Fit For Life Group, a market leader in fitness equipment and yoga accessories, has partnered with Nutriband to create innovative products for a wide range of consumers.